TRCT
LEGN icon

Tower Research Capital (TRC)’s Legend Biotech LEGN Stock Holding History

Tower Research Capital (TRC)’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1K Buy
626
+416
+198% +$11.2K ﹤0.01% 3644
2026
Q1 		$3.8K Sell
210
-1,117
-84% -$21.3K ﹤0.01% 4266
2025
Q4 		$28.8K Sell
1,327
-1,685
-56% -$48.3K ﹤0.01% 2829
2025
Q3 		$98.2K Buy
3,012
+1,328
+79% +$49K ﹤0.01% 2006
2025
Q2 		$59.8K Sell
1,684
-1,447
-46% -$46.9K ﹤0.01% 2817
2025
Q1 		$106K Sell
3,131
-1,349
-30% -$48.4K ﹤0.01% 1742
2024
Q4 		$146K Buy
4,480
+3,496
+355% +$145K ﹤0.01% 1919
2024
Q3 		$48K Buy
984
+737
+298% +$39.3K ﹤0.01% 2743
2024
Q2 		$10.9K Sell
247
-1,274
-84% -$58.8K ﹤0.01% 4114
2024
Q1 		$85.3K Sell
1,521
-385
-20% -$23.2K ﹤0.01% 1911
2023
Q4 		$115K Buy
1,906
+1,624
+576% +$103K ﹤0.01% 2543
2023
Q3 		$18.9K Sell
282
-13,905
-98% -$966K ﹤0.01% 3427
2023
Q2 		$979K Buy
14,187
+13,135
+1,249% +$858K 0.03% 525
2023
Q1 		$51K Sell
1,052
-308
-23% -$15.1K ﹤0.01% 2474
2022
Q4 		$68K Sell
1,360
-2,746
-67% -$133K ﹤0.01% 2128
2022
Q3 		$167K Sell
4,106
-2,336
-36% -$110K ﹤0.01% 2101
2022
Q2 		$354K Buy
6,442
+5,160
+402% +$218K 0.01% 1359
2022
Q1 		$47K Buy
1,282
+500
+64% +$19.8K ﹤0.01% 2782
2021
Q4 		$36K Buy
782
+490
+168% +$24.9K ﹤0.01% 3048
2021
Q3 		$15K Sell
292
-229
-44% -$9.53K ﹤0.01% 3983
2021
Q2 		$21K Sell
521
-886
-63% -$30.1K ﹤0.01% 3846
2021
Q1 		$41K Sell
1,407
-5,292
-79% -$144K ﹤0.01% 3290
2020
Q4 		$188K Buy
6,699
+6,629
+9,470% +$191K 0.01% 1759
2020
Q3 		$2K Buy
+70
New +$2.36K ﹤0.01% 4599

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Tower Research Capital (TRC)'s LEGN Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Legend Biotech (LEGN) stake by 198% in Q2 2026, buying an estimated $11.2K and bringing the position to 626 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3644.

Tower Research Capital (TRC) first reported a position in LEGN in Q3 2020 and has held it in 24 quarters since. The position peaked at $979K in Q2 2023. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Tower Research Capital (TRC) held 626 shares of Legend Biotech worth $18.1K as of Q2 2026.
  • Tower Research Capital (TRC) bought 416 Legend Biotech shares in Q2 2026, an estimated $11.2K.
  • Legend Biotech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3644 holding.
  • Tower Research Capital (TRC) first reported a position in Legend Biotech in Q3 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Legend Biotech position peaked at $979K in Q2 2023.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.